Campari Wants to Swap Beer for Aperol Spritz in Middle America

Davide Campari-Milano NV’s new CEO Simon Hunt is prioritizing expansion of the Aperol Spritz in the US, aiming to make it as ubiquitous in states like Texas as it is in Milan and Berlin. Highlighting the opportunity, Hunt said roughly half of Americans have never heard of Aperol Spritz, signaling significant headroom for brand penetration and US sales growth under the new management’s marketing push.

Analysis

Market structure: A sustained US push for Aperol Spritz benefits Campari (CPR.MI) directly and premium spirits platforms (DEO, STZ) indirectly, while commoditized US beer incumbents (BUD, TAP) face share risk. Aperol SKUs carry materially higher ASPs and typical gross margins ~200–300bps above mass beer, implying potential EBITDA upside if US volumes scale from essentially 0 to low-single-digit share of on‑premise cocktail occasions within 24 months. Downstream, expect upward pressure on Prosecco (Glera) spot prices and export volumes; a 5–15% price move in next 12 months is plausible if demand accelerates.

Risk assessment: Tail risks include US state-level excise changes, three‑tier distribution blockages, and a Prosecco supply shock concentrated in Veneto; any of these can erase near-term margin gains. Immediate (days–weeks) effects are marketing spend and on‑premise placements; short term (months) is retail trial and SKU rollouts; long term (2–4 years) is cultural adoption. Hidden dependencies: distribution agreements, slotting fees, and bartenders’ menu uptake are the gating items. Catalysts: summer seasonality (May–Aug), major festival tie‑ins, or celebrity endorsements could accelerate trials.

Trade implications: Direct long in CPR.MI for 12–24 months is a high-conviction play if management executes US distribution; offset with a small short in BUD/TAP for relative exposure. Use 9–15 month call spreads on CPR.MI to lever upside while capping premium; consider long calls on DEO/STZ as sector hedges. Rotate 1–3% portfolio weight from mass beer names into premium spirits/RTD over next 3–6 months ahead of summer testing and reportable US volume inflection points.

Contrarian angles: The market underestimates three‑tier inertia and price sensitivity — US beer is habitual and cheaper, so realistic upside is gradual (3–7 years) not immediate. Historical parallel: tequila premiumization took ~10 years with episodic spikes; Aperol can follow a compressed 3–5 year path but only with heavy and repeated on‑premise promotion. Unintended outcome: Prosecco price spikes could force substitution to domestic sparkling or proprietary RTD Spritzes, capping Campari’s margin expansion.

Key Decisions for Investors

• Establish a 2–3% long position in Campari (CPR.MI) with a 12–24 month horizon; size initial entry to limit portfolio downside and add only if US aperitif volume growth >10% YoY for two consecutive quarters or management guides US net revenue growth >8% YoY. Set tactical stop-loss at -18% from entry.
• Initiate a hedged pair trade: long CPR.MI 2% vs short Anheuser‑Busch InBev (BUD) 1–2% to express premiumization over commodity beer; rebalance quarterly and close if relative outperformance exceeds +15% or if beer volumes recover to pre‑pandemic levels for two quarters.
• Buy a 9–15 month call spread on CPR.MI (buy ~15% OTM, sell ~35% OTM) sized to target a 3x payoff on a successful US rollout; alternatively, buy 9–12 month calls on Diageo (DEO) or Constellation (STZ) as diversified exposure to premium spirits growth.
• Reduce exposure to commodity beer names/ETFs (e.g., TAP, broad beer ETF) by 1–3% and rotate into premium spirits/RTD names (DEO, STZ) over the next 3–6 months, concentrating purchases ahead of the US summer season (May–Aug) when trial rates peak.